Bristol-myers Squibb Compnay

Syngene International Limited

Shiwei Tao

Yan Shi

Hao Zhang

Peter Tai Wah Cheng

Jun Shi

Jun Li

Robert F Kaltenbach, Iii

James R Corte

Lawrence J Kennedy

Ying Wang

Tianan Fang

Sutjano Jusuf

Steven J Walker

Kumaravel Selvakumar

Suresh Dhanusu

Peter T W Cheng

Ramesh Babu Reddigunta

Shung C Wu

Jeffrey A Robl

Sean Chen

David J Donnelly

Lidet A Negash

Tritin Tran

Joonyoung Kim

Ramesh Badu Reddigunta

Iii Robert F Kaltenbach

Robert F Kaltenbach Iii

Robert F Iii Kaltenbach

Peter TW Cheng

The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Cyclobutyl carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Oxabicyclo acids as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

Cyclohexyl acid triazole azines as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Cyclopropanecarboxylic acid GPR120 modulators

The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments. 

Bicyclo[2.2.2]acid GPR120 modulators

Growing community of inventors

Hillsborough, NJ, United States of America

Shiwei Tao